{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:10:52Z","timestamp":1789096252491,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Program for Innovative Research Team in Science and Technology"},{"name":"Department of Finance of Hebei Province","award":["2022016"],"award-info":[{"award-number":["2022016"]}]},{"name":"Medical Health Science and Technology Project of Hebei Provincial Health Commission","award":["20230781"],"award-info":[{"award-number":["20230781"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Herein, we aimed to evaluate the efficacy and safety of camrelizumab combined with docetaxel and carboplatin as a neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma (OSCC). Fifty-one patients with OSCC, treated from July 2020 to October 2022, were analyzed. Of them, 41 patients underwent surgery 4\u20138\u00a0weeks after undergoing two\u00a0cycles of camrelizumab (200\u00a0mg IV Q3W) combined with docetaxel (75\u00a0mg\/m2 IV Q3W) and carboplatin (area under the curve\u2009=\u20095\u20136 IV Q3W). The primary endpoint was the pathological complete response rate. All 51 patients (100%) experienced treatment-related grades 1\u20132 adverse events, and 2 patients (3.9%) experienced grade 4 events (including elevated alanine transaminase\/aspartate transferase levels and Guillain\u2013Barre syndrome). Fifty patients were evaluated for the treatment efficacy. Of them, 13 achieved complete response, and the objective response rate was 74%. Only 41 patients underwent surgical treatment. The pathological complete response rate was 17.1%, the major pathological response rate was 63.4%, and the R0 resection rate was 100%. Approximately 22% of the patients had tumor regression grades 0. Eight patients (19.5%) developed surgery-related complications. The median follow-up time was 18\u00a0months (range: 3\u201329\u00a0months). Four patients experienced disease progression, while four died. The median disease-free survival and overall survival were not reached. Camrelizumab combined with docetaxel and carboplatin is an effective and safe neoadjuvant treatment for locally advanced OSCC. This regimen may afford a potential strategy to treat patients with locally advanced OSCC.<\/jats:p>","DOI":"10.1093\/dote\/doad073","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T12:36:04Z","timestamp":1704717364000},"source":"Crossref","is-referenced-by-count":2,"title":["Clinical study of camrelizumab combined with docetaxel and carboplatin as a neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma"],"prefix":"10.1093","volume":"37","author":[{"given":"Guo-Liang","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University , Shijiazhuang, Hebei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Kun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University , Shijiazhuang, Hebei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-You","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University , Shijiazhuang, Hebei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Gang","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University , Shijiazhuang, Hebei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Dan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University , Shijiazhuang, Hebei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University , Shijiazhuang, Hebei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University , Shijiazhuang, Hebei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University , Shijiazhuang, Hebei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Li","family":"Mi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University , Shijiazhuang, Hebei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University , Shijiazhuang, Hebei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,6]]},"reference":[{"key":"2024040305385162800_ref1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2024040305385162800_ref2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/nyas.14508","article-title":"Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma","volume":"1482","author":"Leng","year":"2020","journal-title":"Ann N Y Acad Sci"},{"key":"2024040305385162800_ref3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2020.08.002","article-title":"Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010","volume":"138","author":"Liu","year":"2020","journal-title":"Eur J Cancer"},{"key":"2024040305385162800_ref4","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2024040305385162800_ref5","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-Line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"2024040305385162800_ref6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10388-022-00970-1","article-title":"First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648\/ONO-4538-50)","volume":"20","author":"Kato","year":"2023","journal-title":"Esophagus"},{"key":"2024040305385162800_ref7","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (Escort): a multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol"},{"key":"2024040305385162800_ref8","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"key":"2024040305385162800_ref9","first-page":"S1","article-title":"Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, open-label, phase II study","volume":"34","author":"Wang","year":"2021","journal-title":"Dis Esophagus"},{"key":"2024040305385162800_ref10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s12957-021-02446-5","article-title":"Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study","volume":"19","author":"Yang","year":"2021","journal-title":"World J Surg Oncol"},{"key":"2024040305385162800_ref11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ijc.33976","article-title":"Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study","volume":"151","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"key":"2024040305385162800_ref12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2024040305385162800_ref13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1442-2050.2008.00910.x","article-title":"Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma","volume":"22","author":"Cao","year":"2009","journal-title":"Dis Esophagus"},{"key":"2024040305385162800_ref14","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jtho.2019.04.004","article-title":"Detecting pathological complete response in esophageal cancer after neoadjuvant therapy based on imaging techniques: a diagnostic systematic review and meta-analysis","volume":"14","author":"De Gouw","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2024040305385162800_ref15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","article-title":"Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Ajani","year":"2019","journal-title":"J Natl Compr Canc NE"},{"key":"2024040305385162800_ref16","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00432-021-03659-7","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China","volume":"148","author":"Zhang","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"2024040305385162800_ref17","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.ejso.2015.03.226","article-title":"Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: a randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation","volume":"41","author":"Klevebro","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"2024040305385162800_ref18","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jso.24596","article-title":"Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: a propensity score-matched analysis comparing toxicity, pathologic outcome, and survival","volume":"115","author":"Goense","year":"2017","journal-title":"J Surg Oncol"},{"key":"2024040305385162800_ref19","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2013.53.6532","article-title":"Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901","volume":"32","author":"Mariette","year":"2014","journal-title":"J Clin Oncol"},{"key":"2024040305385162800_ref20","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"2024040305385162800_ref21","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ"},{"key":"2024040305385162800_ref22","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/oncolo\/oyab011","article-title":"Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma","volume":"27","author":"He","year":"2022","journal-title":"Oncologist"},{"issue":"6","key":"2024040305385162800_ref23","doi-asserted-by":"crossref","first-page":"S1292","DOI":"10.1016\/j.annonc.2020.10.148","article-title":"A prospective phase II clinical trial exploring neoadjuvant immunotherapy combined with chemotherapy in resectable thoracic esophageal squamous cell cancer (TESCC) with multi-station lymph node metastases (NICE study): preliminary results","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"key":"2024040305385162800_ref24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00262-012-1388-0","article-title":"Chemoimmunotherapy: reengineering tumor immunity","volume":"62","author":"Chen","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"2024040305385162800_ref25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.797426","article-title":"Neoadjuvant immunotherapy combined chemotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma: a propensity score-matched study","volume":"11","author":"Hong","year":"2021","journal-title":"Front Oncol"},{"key":"2024040305385162800_ref26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003497","article-title":"Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma","volume":"10","author":"Yang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2024040305385162800_ref27","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.21037\/atm-21-3352","article-title":"Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma","volume":"9","author":"Yang","year":"2021","journal-title":"Ann Transl Med"},{"key":"2024040305385162800_ref28","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.21037\/jtd-21-340","article-title":"Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma","volume":"13","author":"Wu","year":"2021","journal-title":"J Thorac Dis"},{"key":"2024040305385162800_ref29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.864533","article-title":"Neoadjuvant sintilimab plus chemotherapy in resectable locally advanced esophageal squamous cell carcinoma","volume":"12","author":"Lv","year":"2022","journal-title":"Front Oncol"},{"key":"2024040305385162800_ref30","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/j.lpm.2013.02.328","article-title":"Diagnosis, treatment and prognosis of Guillain-Barr\u00e9 syndrome (GBS)","volume":"42","author":"Van Doorn","year":"2013","journal-title":"Presse Med"},{"key":"2024040305385162800_ref31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.595655","article-title":"Immune-related neurological toxicities of PD-1\/PD-L1 inhibitors in cancer patients: a systematic review and meta-analysis","volume":"11","author":"Tian","year":"2020","journal-title":"Front Immunol"},{"key":"2024040305385162800_ref32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1053\/j.gastro.2019.10.039","article-title":"Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer","volume":"158","author":"Azad","year":"2019","journal-title":"Gastroenterology"},{"key":"2024040305385162800_ref33","doi-asserted-by":"crossref","first-page":"e1022","DOI":"10.1097\/SLA.0000000000003727","article-title":"Prognostic impact of postoperative lymph node metastases after neoadjuvant chemoradiotherapy for locally advanced squamous cell carcinoma of esophagus: from the results of NEOCRTEC5010, a randomized multicenter study","volume":"274","author":"Leng","year":"2021","journal-title":"Ann Surg"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/37\/4\/doad073\/57138994\/doad073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/37\/4\/doad073\/57138994\/doad073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T05:39:22Z","timestamp":1712122762000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doad073\/7512639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,6]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,1,6]]},"published-print":{"date-parts":[[2024,4,2]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doad073","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,1,6]]},"article-number":"doad073"}}